Poly-ɛ-caprolactone nanocapsules loaded with copaiba essential oil reduce inflammation and pain in mice

Pinto, Erveton Pinheiro; Costa, Sarah O.A.M.; D'Haese, Cecile; Nysten, Bernard; Machado, Francisco Paiva; Rocha, Leandro; Souza, Tiago Marcolino de; Beloqui, Ana; Machado, Renes R.; Araújo, Raquel Silva

doi:10.1016/j.ijpharm.2023.123147

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the absence of a pharmacokinetic study of 4-PSCO, to better understand the compound’s bioavailability in the body, is one of the limitations of our study. Despite the absence of this study, all these aspects represent pivotal attributes deserving consideration and are consistent with results previously demonstrated by other researchers [ 21 , 101 , 102 ]. This prolongation of the antinociceptive effect contributes to mitigating the inflammatory process.…”

Section: Discussionsupporting

confidence: 91%

4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension—A Promising Breakthrough in Pain Management: Comprehensive Molecular Docking, Formulation Design, and Toxicological and Pharmacological Assessments in Mice

da Fonseca,

Prado,

Paltian

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Therapies for the treatment of pain and inflammation continue to pose a global challenge, emphasizing the significant impact of pain on patients’ quality of life. Therefore, this study aimed to investigate the effects of 4-(Phenylselanyl)-2H-chromen-2-one (4-PSCO) on pain-associated proteins through computational molecular docking tests. A new pharmaceutical formulation based on polymeric nanocapsules was developed and characterized. The potential toxicity of 4-PSCO was assessed using Caenorhabditis elegans and Swiss mice, and its pharmacological actions through acute nociception and inflammation tests were also assessed. Our results demonstrated that 4-PSCO, in its free form, exhibited high affinity for the selected receptors, including p38 MAP kinase, peptidyl arginine deiminase type 4, phosphoinositide 3-kinase, Janus kinase 2, toll-like receptor 4, and nuclear factor-kappa β. Both free and nanoencapsulated 4-PSCO showed no toxicity in nematodes and mice. Parameters related to oxidative stress and plasma markers showed no significant change. Both treatments demonstrated antinociceptive and anti-edematogenic effects in the glutamate and hot plate tests. The nanoencapsulated form exhibited a more prolonged effect, reducing mechanical hypersensitivity in an inflammatory pain model. These findings underscore the promising potential of 4-PSCO as an alternative for the development of more effective and safer drugs for the treatment of pain and inflammation.

show abstract

Section: Discussionsupporting

confidence: 91%